ID: MRFR/HC/6970-HCR | February 2021 | Region: Global | 111 pages
$1.84 Billion
5.8%
North America
2022-2030
Vitiligo Treatment Market is expected to cross USD 1.84 Billion by 2025 at a CAGR of 5.6%.
Market Synopsis
Vitiligo is a pigmentation disorder in which the skin's pigment-making cells known as melanocytes are lost or destroyed. As a result of which, well-defined white patches appear on the skin. Patches may occur on one section or all over the body and later may join together.
Market Influencer
Increasing prevalence of investments by government bodies on healthcare infrastructure is positively influencing the vitiligo treatment market.
Market Drivers
Market Restraints
Segmentation
By Type
non-segmental Vitiligo: It is also known as generalized or bilateral vitiligo. It is the largest segment as the occurrence of non-segmental vitiligo is 9 out of 10 people.
Segmental vitiligo: It is also known as unilateral vitiligo. It spreads rapidly in the affected areas.
By Treatment Type
Therapy: The therapy is further segmented into light therapy and de-pigmentation.
Surgery: Skin grafting, blister grafting are the types of surgery for treating vitiligo.
Medication: It is forecasted to be the largest segment due to the number of FDA approvals, drugs in the pipeline, and the cost of vitiligo treatment through medication is less as compared to the other treatment methods.
By End-User
Hospitals: The largest segment, hospitals are usually the primary points for diagnosis, treatment, and rehabilitation of individuals suffering from ailments or injuries. Growing awareness and increasing efficiency of medical services are projected to drive the growth of this segment during the forecast period.
Aesthetic Clinics: These clinics are widely known for improving cosmetic appearance.
By Region
Americas: The largest regional market. The prevalence of vitiligo is high in the Americas; the region also has a well-established healthcare industry.
Europe: It is estimated to be the second-largest market, due to the presence of key manufacturers and increasing research and development funding along with the undergoing rigorous clinical trial.
Asia-Pacific: The fastest-growing regional market, Asia-Pacific, is witnessing a surge in the number of people undergoing treatments for vitiligo, and many market players are investing in the Asia-Pacific region as it has a population of approximately 4.3 billion people.
Middle East & Africa: The smallest market due to limited healthcare infrastructure, the dearth of technological advancements in the pharmaceutical sector.
Key Players
Report Attribute/Metric | Details |
---|---|
Market Size |
|
CAGR | 5.6% (2019-2025) |
Base Year | 2019 |
Forecast Period | 2020-2027 |
Historical Data | 2018 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type, Treatment Type, End-User |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Novartis AG (Basel, Basel-Stadt), Allergan, Inc. (Dublin, Coolock), Clinuvel Pharmaceuticals Limited (Melbourne, Victoria), Astellas Pharma Inc. (Northbrook, IL), Bausch Health Companies Inc. (Laval, Quebec), STRATA Skin Sciences (Horsham, PA), Reddy’s Laboratories Ltd. (India), Eli Lilly Company (Indianapolis, Indiana), Incyte Corporation (Wilmington, Delaware), AstraZeneca AB (Cambridge, Cambridgeshire), Epizyme, Inc. (Cambridge, MA), Baxter International Inc. (Deerfield, Illinois), Pfizer Inc. (New York) |
Key Market Opportunities | New product launches and R&D Amongst major key Players |
Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
vitiligo treatment market is projected grow at approximately 5.6% CAGR during the assessment period (2019-2025).
The valuation of the global vitiligo treatment market is estimated to increase to USD 1.84 BN by the end of 2025.
Increasing investments by government bodies and the emergence of new novel therapy and drugs are the major tailwinds pushing the growth of the global vitiligo treatment market.
North America holds the largest share in the global vitiligo treatment market, followed by Europe and the Asia Pacific, respectively.
STRATA Skin Sciences (Horsham, PA), Bausch Health Companies Inc. (Laval, Quebec), Reddy’s Laboratories Ltd. (India), Clinuvel Pharmaceuticals Limited (Melbourne, Victoria), Allergan, Inc. (Dublin, Coolock), Astellas Pharma Inc. (Northbrook, IL), Eli Lilly Company (Indianapolis, Indiana), Novartis AG (Basel, Basel-Stadt), Incyte Corporation (Wilmington, Delaware), Epizyme, Inc. (Cambridge, MA), AstraZeneca AB (Cambridge, Cambridgeshire), Baxter International Inc. (Deerfield, Illinois), and Pfizer Inc. (New York), are some of the major players operating in the global vitiligo treatment market.